Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Cancer cell - 9 Sept 2013

Leung-Hagesteijn Chungyee, Erdmann Natalie, Cheung Grace, Keats Jonathan J, Stewart A Keith, Reece Donna E, Chung Kim Chan, Tiedemann Rodger E

Abstract excerpt

Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial. We report the existence of a progenitor organization in primary MM that recapitulates maturation stages between B cells and plasma cells and that contributes to clinical PI resistance. Xbp1s(-) tumor B cells and pre-plasmablasts survive therapeutic PI, preventing cure, while maturation arrest of MM before the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activating Transcription Factor 6
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Plasma Cells

Share to Precursor Cells, B-Lymphoid

Share to Proteasome Inhibitors

Share to Regulatory Factor X Transcription Factors

Share to X-Box Binding Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 24029229
DOI: 10.1016/j.ccr.2013.08.009
PMCID: PMC4118579

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.PMID 24029229Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaSemantic proximity Read ↗

CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagySemantic proximity Read ↗

Disruption of IRElα through its Kinase Domain Attenuates Multiple MyelomaSemantic proximity Read ↗

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read ↗

Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistanceSemantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

Autophagy-related mechanisms for treatment of multiple myelomaSemantic proximity Read ↗

Endoplasmic reticulum stress in the development of multiple myeloma and drug resistanceSemantic proximity Read ↗

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read ↗

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.